Subsequently, eprenetapopt in combination with azacytidine was investigated in a phase Ib/II trial in patients with TP53 mutant myelodysplastic syndromes (MDS) (n = 40) or AML (n = 11) [54]. This evidence concerns the gene TP53 and myelodysplastic syndrome.